



ADDRESSING CURRENT CHALLENGES IN ANTIVIRAL THERAPIES AGAINST EMERGING RNA VIRUSES

Karine ALVAREZ

Laboratoire d'Architecture et Fonction des Macromolécules Biologiques, UMR 7257 CNRS, Campus de Luminy, 13288 Marseille Cedex 09, France. e-mail: karine.alvarez@univ-amu.fr

The current Covid-19 crisis has profoundly reshaped our vision of antiviral therapies and our expectations about repositioning molecules. The successes and failures of the past have paved the way for a different manner of thinking about effective antivirals when a pandemic, such as the one we are experiencing, arrives. We must be able to react quickly and efficiently.

Today, the successful development of an antiviral depends on the understanding of its mode of action and its limitations. This essential insight requires the perfect knowledge of the viral target to be reached as well as the access to biochemical assays and structural models.

Through several examples of work aimed at developing antivirals against emerging viruses, mostly neglected, we will try to give an overview of the methods used and the results obtained.